MannKind Q1 revenue $66M (+63% YoY); net income $11M; FDA Fast Track for MNKD-101

MANNKIND CORP

2024-Q1 EPS reported $0.04 revenue$66,263,000

Total revenues $66.3M (+63% YoY); GAAP net income $11M; non-GAAP net income $15M.
Tyvaso DPI royalties surged 94% to $22.7M; collaborations & services revenue up 118% to $24.8M.
Afrezza net revenue $14.4M (+16%); V-Go down 16% to $4.3M.
Cash and investments $304.5M; repaid ~$37M of secured debt in early April.
FDA Fast Track and IND clearance for MNKD-101 (clofazimine inhaled suspension).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MANNKIND CORP reported the quarter ended March 31, 2024 results: revenue Total revenues of $66M, net income Net income of $11M.

Period: the quarter ended March 31, 2024
Revenue: Total revenues of $66M
Net income: Net income of $11M
Result: reported results

Exact text from the filing

CORPORATION REPORTS 2024 FIRST QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 • 1Q 2024 Net income of $11M; Non-GAAP net income of $15M • $304M of cash and cash equivalents and investments at March 31, 2024 • In early April, repaid

View on SEC.gov

Browse all earnings releases →

MANNKIND CORP filing history →

Source: SEC EDGAR

accession 0000950170-24-055622

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.